Google
LONA — LEONABIO, INC. (Healthcare >> Biotechnology)
LONA FAQ
What is LONA's ROE?
LEONABIO, INC. reports a Return on Equity (ROE) of -262.49%.
What is LONA's dividend yield?
LEONABIO, INC. offers a dividend yield of 0.00%.
What is LONA's Deepscope Quality Score?
Deepscope rates LONA's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LONA?
Deepscope's AI Timing Score for LONA is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LONA belong to?
LEONABIO, INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 8.22
Price
-0.39
(-4.53%)
Day Change
|
|
|---|
LONA, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 75 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 8.22 |
| PBV / Sector |
1.64 / 4.63
|
| Earning Per Share | -13.12 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.41 M
GREAT
|
| Average 1W Daily Value |
0.19 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:02 |
| Symbol | LONA |
| Name | LEONABIO, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 9.39 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 81.07 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 18706 North Creek Parkway, Bothell, WA, United States, 98011
Phone: 425 620 8501
Website: https://www.leonabio.com
Sector: Healthcare >> Biotechnology
Description: LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer's disease and Parkinson's disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
